D-1093-2023 Class II Terminated
FDA drug recall D-1093-2023 was initiated by Parker Laboratories, Inc. on Aug 2, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jun 3, 2024). Affected quantity: 50.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 30, 2023
- Initiation Date
- Aug 2, 2023
- Termination Date
- Jun 3, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 50
Product description
Helix CBD Clinical Cream (Menthol 7.4%), packaged in a)3 gm pouches (NDC30775-054-01), b)2 fl. oz. tubes (NDC 30775-054-02), and c) 4 fl. oz. tubes (NDC 30775-054-04), Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide within the United States, Singapore, Korea and Hong Kong
Code information
Lot #: a) J1121011, Exp. Date 12/21/2023, b) A0921009, Exp. Date 8/18/2023, c) A0921008, Exp. Date 8/18/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1093-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026